Results 11 to 20 of about 18,708 (185)

An Insight Into Intestinal Microbiota of Spontaneously Hypertensive Rats After Valsartan Administration

open access: yesDose-Response, 2021
It has been proven a close relationship between intestinal microbiota and hypertension. Valsartan is a widely used ARB antihypertensive drug; so far, the effect of valsartan on intestinal microbiota remains largely unexplored.
Ying-Zi Qi   +5 more
doaj   +1 more source

Comparative effects of valsartan plus cilnidipine or hydrochlorothiazide on nocturnal home blood pressure

open access: yesThe Journal of Clinical Hypertension, 2021
We tested our hypothesis that, in hypertensive patients with higher nocturnal home systolic blood pressure (HSBP) at baseline, a valsartan/cilnidipine (80/10 mg) combination would reduce nocturnal HSBP more markedly than a valsartan/hydrochlorothiazide ...
Takeshi Fujiwara   +4 more
doaj   +1 more source

Role of sacubitril-valsartan in the prevention of atrial fibrillation occurrence in patients with heart failure: A systematic review and meta-analysis of randomized controlled trials.

open access: yesPLoS ONE, 2022
ObjectiveHeart failure (HF) and atrial fibrillation (AF) are often coexisting. They have common risk factors and pathophysiologic mechanisms. Sacubitril/valsartan has shown efficacy and tolerability in patients with HF.
Xuehui Liu   +4 more
doaj   +2 more sources

EFFECT OF SACUBITRIL/VALSARTAN ON NATRIURESIS, DIURESIS AND BLOOD PRESSURE IN HYPERTENSIVE PATIENTS

open access: yesРациональная фармакотерапия в кардиологии, 2017
Aim. To study the effect of sacubitril/valsartan compared with valsartan on natriuresis, diuresis, blood pressure (BP) and the level of biomarkers in hypertensive patients.Material and methods.
Zh. D. Kobalava   +3 more
doaj   +1 more source

Combined Angiotensin Receptor–Neprilysin Inhibitors Improve Cardiac and Vascular Function Via Increased NO Bioavailability in Heart Failure

open access: yesJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2018
BackgroundThere is a paucity of data about the mechanisms by which sacubitril/valsartan (also known as LCZ696) improves outcomes in patients with heart failure. Specifically, the effects of sacubitril/valsartan on vascular function and NO bioavailability
Rishi K. Trivedi   +7 more
doaj   +1 more source

Sacubitril/Valsartan and Ivabradine Attenuate Left Ventricular Remodelling and Dysfunction in Spontaneously Hypertensive Rats: Different Interactions with the Renin–Angiotensin–Aldosterone System

open access: yesBiomedicines, 2022
This study investigated whether sacubitril/valsartan and ivabradine are able to prevent left ventricular (LV) fibrotic remodelling and dysfunction in a rat experimental model of spontaneous hypertension (spontaneously hypertensive rats, SHRs) and whether
Fedor Simko   +9 more
doaj   +1 more source

Depression associated with valsartan, angiotensin II receptor antagonist; case report and review of the literature

open access: yesPsychiatry and Clinical Psychopharmacology, 2021
Severe depression with suicidal ideation associated with the use of the valsartan , an angiotensin receptor antagonist, is reported. The patient, who was unresponsive to antidepressant medication with two different groups, dramatically recovered ...
Numan Konuk, Mustafa Aydın, Ömer Akay
doaj  

Dual Angiotensin Receptor and Neprilysin Inhibitor Ameliorates Portal Hypertension in Portal Hypertensive Rats

open access: yesPharmaceutics, 2020
Background: Portal hypertension is characterized by exaggerated activation of the renin-angiotensin-aldosterone axis. Natriuretic peptide system plays a counter-regulatory role, which is modulated by neprilysin.
Shao-Jung Hsu   +6 more
doaj   +1 more source

Sacubitril/Valsartan Initiation Among Veterans Who Are Renin‐Angiotensin‐Aldosterone System Inhibitor Naïve With Heart Failure and Reduced Ejection Fraction

open access: yesJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2021
Background Sacubitril/valsartan, a first‐in‐class angiotensin receptor neprilysin inhibitor, received US Food and Drug Administration approval in 2015 for heart failure with reduced ejection fraction (HFrEF).
April F. Mohanty   +14 more
doaj   +1 more source

Valsartan in Combination with Tripterygium Glycosides Protects against Chronic Nephritis via the Toll-Like Receptor 4 Pathway

open access: yesAnalytical Cellular Pathology, 2022
Objective. Valsartan has been studied to exert effects on kidney disease. However, the concrete function of valsartan in combination with tripterygium glycosides in chronic nephritis remained largely unknown. The study was designed to unravel the impacts
Jiabao Dong   +3 more
doaj   +1 more source

Home - About - Disclaimer - Privacy